Antidotes were statistically significantly more frequently given in Canada as compared to other participating countries. The use of antidotes was comparable for initial and long-term treatment. Vitamin K was given to 23 (1.2%) patients, one (0.05%) patient received protamin sulfate and seven (0.4%) patients received fresh frozen plasma. Of the patients with at least one major hemorrhage, 19 (41.3%) received an antidote. Some form of antidote was given to 26 (14.4%) patients with a hemorrhage. We investigated 1877 patients treated for venous thromboembolism included in three large clinical trials, of which 181 (9.6%) had a total of 225 adjudicated bleeding episodes 46 hemorrhages being designated as major. Interestingly, it is unknown how often the use of an antidote is necessary in clinical practice. Several new anticoagulants have been developed that are likely to have some risk of bleeding complications, for which no specific antidotes are available. When a bleeding complication occurs during therapy with heparin or vitamin K antagonists, there is an option to give a specific antidote.
0 kommentar(er)
